Juergen Wolf Selected Research

nazartinib

1/2022	Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
1/2020	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Juergen Wolf Research Topics

Disease

9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 03/2014
9	Neoplasms (Cancer) 01/2021 - 10/2010
9	Lung Neoplasms (Lung Cancer) 01/2021 - 06/2010
3	Disease Progression 01/2020 - 03/2014
3	Adenocarcinoma of Lung 01/2019 - 04/2013
2	Pneumonia (Pneumonitis) 01/2020 - 01/2018
2	Vomiting 01/2017 - 03/2014
1	Exanthema (Rash) 01/2020
1	Colitis 01/2020
1	Melanoma (Melanoma, Malignant) 01/2020
1	Adenocarcinoma 01/2019
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2018
1	Fatigue 01/2018
1	Carcinoma (Carcinomatosis) 01/2018
1	Hyperphosphatemia 01/2018
1	Constipation 01/2018
1	Brain Neoplasms (Brain Tumor) 01/2017
1	Nausea 01/2017
1	Dehydration (Water Stress) 03/2014
1	Diarrhea 03/2014
1	Hypophosphatemia 03/2014
1	Depressive Disorder (Melancholia) 03/2010
1	Bipolar Disorder (Manic Depressive Psychosis) 03/2010
1	Colorectal Neoplasms (Colorectal Cancer) 08/2005
1	Hodgkin Disease (Hodgkin's Disease) 07/2005
1	Lymphoma (Lymphomas) 11/2003
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 11/2003
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 11/2003

Drug/Important Bio-Agent (IBA)

4	Anaplastic Lymphoma KinaseIBA 01/2019 - 11/2003
2	nazartinibIBA 01/2022 - 01/2020
2	Tyrosine Kinase InhibitorsIBA 01/2022 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 08/2005
2	PlatinumIBA 01/2020 - 01/2017
2	Alanine Transaminase (SGPT)IBA 01/2020 - 01/2017
2	ceritinibIBA 01/2017 - 03/2014
2	CrizotinibIBA 03/2014 - 04/2013
1	Circulating Tumor DNAIBA 01/2021
1	A 17 (A-17)IBA 01/2021
1	VemurafenibIBA 01/2020
1	NivolumabIBA 01/2020
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2020
1	ErbB Receptors (EGF Receptor)IBA 01/2020
1	AfatinibIBA 01/2019
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019
1	Biomarkers (Surrogate Marker)IBA 01/2019
1	CreatinineIBA 01/2018
1	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2018
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018
1	infigratinibIBA 01/2018
1	L 644711 (B-3(+))IBA 01/2018
1	Docetaxel (Taxotere)FDA Link 01/2017
1	Pemetrexed (MTA)FDA Link 01/2017
1	AZD 6244IBA 01/2017
1	Carboplatin (JM8)FDA LinkGeneric 01/2017
1	Cisplatin (Platino)FDA LinkGeneric 01/2017
1	Transaminases (Aminotransferases)IBA 03/2014
1	Phosphotransferases (Kinase)IBA 04/2013
1	Aripiprazole (Abilify)FDA Link 03/2010
1	Antipsychotic Agents (Antipsychotics)IBA 03/2010
1	Citalopram FDA LinkGeneric 03/2010
1	Fluorouracil (Carac)FDA LinkGeneric 08/2005
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 08/2005
1	Carcinoembryonic AntigenIBA 08/2005
1	Leucovorin (Folinic Acid)FDA Link 08/2005
1	Interleukin-2 (IL2)IBA 08/2005
1	Irinotecan (Camptosar)FDA LinkGeneric 08/2005
1	Peptides (Polypeptides)IBA 08/2005
1	Chemokine CCL17IBA 07/2005
1	Proteins (Proteins, Gene)FDA Link 07/2005
1	Pyridinolcarbamate (P23)IBA 11/2003

Therapy/Procedure

10	Therapeutics 01/2022 - 07/2005
5	Drug Therapy (Chemotherapy) 01/2020 - 08/2005
3	Palliative Care (Palliative Therapy) 03/2012 - 06/2010
1	Drug Tapering 01/2020
1	Radiotherapy 01/2018
1	Adjuvant Chemotherapy 01/2017